Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Influence of Plasma Exchange on Rituximab Pharmacokinetics
NCT00820469Phase 4Completed
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Sep 2008
- Primary completion
- Nov 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label trial of rituximab in autoimmune disease and kidney transplant rejection (2 arms), sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Area Under the Concentration Curve at 3 months. Started Sep 2008; status: completed.
02
Drugs
rituximab
03
Conditions
autoimmune diseasekidney transplant rejection
Beyond the preview
Go deeper on NCT00820469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00820469.